New approaches and consequences for elderly cancer patients with focus on melanoma
We present modified NCCN evidence blocks to classify clinical benefit for elderly metastatic renal cell carcinoma patients.
The efficacy of newly registered therapies for metastatic melanoma obtained high scores for clinical effect and underscores the relevance to seriously consider these novel treatment approaches in the elderly.
The CD4+ T cell compartment of young melanoma patients shows strong signs of activation, whereas these signs are lacking in CD4+ T cells of old melanoma patients.
A Dutch registry demonstrates that treatment with ipilimumab for metastatic melanoma is equally effective in elderly and younger patients, is safe in patients ≥ 65 years and has similar efficacy and toxicity for both genders.
Early development of hypophosphatemia during imatinib treatment does not predict treatment efficacy.